Analysts Upgraded These 3 Healthcare Stocks Week Ending Nov 18th

Wall St. Watchdog reveals information about companies for which stock analysts upgraded shares in the Healthcare sector for the week ending November 18th, 2011.

  • Amylin Pharma (NASDAQ:AMLN): Robert W. Baird upgraded its rating on this company from Neutral to Outperform and changed its price target from $13 to $15 on Nov 14th. The shares recently traded at $10.21, down $0.24, or 2.3% since the analyst’s rating. About the company: Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes. Get the most recent company news and stock data here >>
  • BioTime (AMEX:BTX): WBB Securities upgraded its rating on this company from Speculative Buy to Buy and changed its price target from $6 to $8 on Nov 16th. The shares recently traded at $4.18, down $0.33, or 7.32% since the analyst’s rating. About the company: BioTime, Inc. researches and develops synthetic solutions that can be used as blood plasma volume expanders, blood replacement solutions during hypothermic surgery, and organ preservation solutions. The Company also operates in regenerative medicine sector, where it develops stem cell related products and technology for diagnostic, therapeutic and research use. Get the most recent company news and stock data here >>
  • Cadence Pharma (NASDAQ:CADX): Oppenheimer upgraded its rating on this company from Underperform to Perform on Nov 17th. The shares recently traded at $4.47, up $0.49, or 12.31% since the analyst’s rating. About the company: Cadence Pharmaceuticals Inc. is a biopharmaceutical company that develops drugs for use in hospitals. The Company produces intravenous APAP for the treatment of acute pain and fever, and omiganan for the prevention of intravascular catheter-related infections. Get the most recent company news and stock data here >>

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>

More from The Cheat Sheet